Outcomes

An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment? 🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/JvH74D2ocI https://t.co/4N1kW214Ak

Links:

Dr. John Cush @RheumNow( View Tweet )
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical

Read Article
20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2
Dr. John Cush @RheumNow( View Tweet )
US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL
Dr. John Cush @RheumNow( View Tweet )
Danish hospital 574 newly diagnosed RA pt, 75% recv glucocorticoids (GC) in 1st yr (55% 1st visit) -- mean dose was 9.3 mg/day, with 46% recv oral tablets & 47% IA steriods injections. 20% had an infection in 1st Yr (RR 1.13; 0.77 to 1.67). Doses declined after 1st visit, but not https://t.co/JcerD61m0t
Dr. John Cush @RheumNow( View Tweet )
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/tQeQz7H7do
Dr. John Cush @RheumNow( View Tweet )
Dietary Interventions in PsA Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050. https://t.co/VLldzkbFU3 https://t.co/5w5wstPawk

Links:

Dr. John Cush @RheumNow( View Tweet )
True or False: RA-associated ILD is considered one of the few RA outcomes that has not improved in the biologic era. See if you got it right in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/L7lAA6lwMp

Links:

Dr. John Cush @RheumNow( View Tweet )
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress. https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1

Links:

Dr. John Cush @RheumNow( View Tweet )
CAR T on purple background

How many CAR-T’s do we need to test drive?

Janet Pope, MD, MPH, FRCPC

CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.

Read Article
laptop

LLMs in SLE: From Patient Education to Clinical Decision Support

Bella Mehta, MBBS, MS

The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this

Read Article
Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu

Links:

Dr. John Cush @RheumNow( View Tweet )
Are we failing in the treatment of RA-ILD? Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026. https://t.co/3UpQQE22Nz https://t.co/ULdCOgh7pY

Links:

Dr. John Cush @RheumNow( View Tweet )
Three Abstracts That May Shape the Future of RA Treatment Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an https://t.co/CaMSHlkbFD
Dr. John Cush @RheumNow( View Tweet )
Treat to Target Works in Elderly Onset RA Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP

Links:

Dr. John Cush @RheumNow( View Tweet )
The pain that inflammation does not explain in SpA and PsA At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Dr. John Cush @RheumNow( View Tweet )
Can you step down #belimumab In well controlled #SLE without flaring? N=22 on #BEL eligible of 152 Able to taper if REM >6/12 No #steroids Normal C3,C4 Neg #antiDNA Remission maintained in pts who reduced dose 6/22 didn’t flare OFF Rx ✅nice #POS1052 #EULAR2026 @RheumNow https://t.co/IEyfRtTGfT

Links:

Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh

Links:

sheila @RHEUMarampa( View Tweet )
EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and

Read Article
#EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL

Links:

Janet Pope @Janetbirdope( View Tweet )
Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360

Jiha Lee @JihaRheum( View Tweet )

Thoracic U/S for #RA-ILD screening? Multicenter study (n=272, Argentina/Denmark/Belgium): 86% sensitivity and 94% NPV. Accessible, no radiation, integrates into clinic flow. Time to build TUS into routine RA-ILD pathways? @RheumNow #EULAR2026 POS1265 https://t.co/FGH5iUstxa

Links:

Jiha Lee @JihaRheum( View Tweet )

Recent Blogs

rheumthought

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose?
Read Article

Hydroxychloroquine for Everyone

Jack Cush, MD
ra.hands2_.JPG
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based on its merit.
Read Post

Choice Overload (and the Way Out)

Jack Cush, MD
paint,choice,overload,color
I recently overheard a very good practicing rheumatologist complain, “why do I need yet another drug for psoriatic arthritis? I have more treatment choices than I have actual PsA patients who need a new or better drug”.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2026 Daily Podcast Day 2c
  • Are your patients with moderate to severe RA getting the appropriate dose? Sponsored by Genentech, Inc
×